PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis
Lists
Only you see this
Abstract
Adding umbralisib to ruxolitinib in patients was well tolerated and may resensitize patients with MF to ruxolitinib without unacceptable rates of adverse events seen with earlier generation PI3Kδ inhibitors. Randomized trials testing umbralisib in the treatment of MF should be pursued.
BibTeX
@inproceedings{moyo2023pi,
author = {Tamara K. Moyo and Ashwin Kishtagari and Matthew T. Villaume and Brandon McMahon and Sanjay Mohan and Tess Stopczynski and Sheau‐Chiann Chen and Run Fan and Yuankai Huo and Hyeonsoo Moon and Yucheng Tang and Cosmin A. Bejan and Merrida Childress and Ingrid Anderson and Kyle Rawling and Rhea M. Simons and Ashley Moncrief and Rebekah Caza and Laura Dugger and Aunshka Collins and Channing V. Dudley and P. Brent Ferrell and Michael Byrne and Stephen A. Strickland and Gregory D. Ayers and Bennett A. Landman and Emily F. Mason and Ruben A. Mesa and Jeanne Palmer and Laura C. Michaelis and Michael R. Savona},
title = {{PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis}},
booktitle = {Clinical},
year = {2023},
doi = {10.1158/1078-0432.ccr-22-3192},
}Loading related content...